Autoimmune Disease Trials 2026: Rheumatoid Arthritis, Lupus, and MS Studies

The autoimmune field has produced more genuine paradigm shifts in the past three years than in the preceding decade. Not incremental improvements on existing biologics — actual paradigm shifts. Anti-CD19 CAR-T data showing drug-free remission in severe refractory SLE. TYK2 inhibitors offering allosteric selectivity that JAK inhibitors couldn't achieve. Combination biologic therapy for IBD delivering remission rates nobody expected. The consistent lesson from 30 years of biologic development — that what works in rheumatoid arthritis doesn't automatically translate to lupus, and what controls Crohn's may not touch MS — still holds. But the mechanisms being targeted in 2026 are more precise than anything that came before, and the early-phase data is correspondingly stronger.

CAR-T Cell Therapy for Autoimmunity: Interpreting the Mackensen Data

Let's be precise about what the Mackensen data actually shows, because it's been described everywhere on a spectrum from "potential cure" to "interesting but too preliminary to matter." Neither framing is accurate.

In the original Nature Medicine 2022 publication, Georg Mackensen's group at Erlangen University Hospital treated five patients with severe refractory SLE using autologous anti-CD19 CAR-T cells manufactured from the patient's own T cells. All five achieved clinical remission. All five discontinued all immunosuppressive medications. The updated 2024 cohort expanded to 15 patients spanning SLE, inflammatory myositis, systemic sclerosis, and antisynthetase syndrome — conditions that share B cell-driven pathology but differ substantially in organ involvement. The results held: clinical remission in all 15, with the earliest patients now at 2+ years of follow-up while remaining off all immunosuppression.

One patient's experience illustrates why the field is paying attention. She had active SLE with nephritis, arthritis, and serositis, was on 10 concurrent immunosuppressive agents including high-dose prednisone and mycophenolate, and had failed belimumab and anifrolumab. Eighteen months after a single CAR-T infusion, she remains off all medications with no clinical or serological evidence of disease activity.

The mechanism is coherent. Anti-CD19 CAR-T cells deplete B cells including pathological autoreactive clones that drive autoimmunity. Following depletion, B cells reconstitute from naive bone marrow precursors that lack the autoreactive specificities of the original pathological population. This is fundamentally different from rituximab-mediated depletion, where reconstituted B cells often re-acquire autoreactive specificity because the depletion is temporary and the bone marrow microenvironment hasn't reset. The CAR-T hypothesis is that the depth and duration of depletion allows the immune system to re-establish tolerance from scratch.

What we genuinely don't know: whether remission is durable beyond 3–5 years, whether reconstituted B cells eventually re-acquire autoreactive specificities in a subset of patients, and critically, whether the efficacy seen in this carefully selected severe refractory cohort applies to patients with earlier or less severe disease. These aren't minor uncertainties. The RESET-SLE trial (NCT05765072) at Stanford and Penn and the RESCUE-myositis trial at Erlangen are designed to answer the Phase 2 question — whether the signal holds in a larger, more controlled setting with pre-specified endpoints.

For patients considering these trials: eligibility currently requires severe refractory disease with failure of at least two biologic or conventional immunosuppressive therapies. The CAR-T manufacturing process takes 4–6 weeks after apheresis. These are available only at specialized centers with CAR-T infrastructure.

Rheumatoid Arthritis in 2026: The JAK Safety Fallout and What Comes Next

The ORAL Surveillance trial (NCT02092467, n=4,362) fundamentally changed RA prescribing patterns. This post-marketing safety study compared tofacitinib to TNF inhibitors in RA patients aged ≥50 with at least one cardiovascular risk factor — a population that reflects a large proportion of real-world RA patients. The results were not subtle: tofacitinib patients had higher rates of major adverse cardiovascular events (MACE, HR 1.33, 95% CI 0.91–1.94) and malignancy (HR 1.48, 95% CI 1.04–2.09) compared to TNF inhibitors. The FDA's 2022 black box warning now applies to the entire JAK inhibitor class, including the more selective upadacitinib and baricitinib.

The JAK1/2/3 selectivity story got complicated. Filgotinib and upadacitinib were supposed to have better safety profiles due to JAK1 selectivity. The FINCH 3 and SELECT-COMPARE trials showed strong efficacy, and post-marketing surveillance data for upadacitinib has been somewhat more reassuring than tofacitinib's. But the class warning stands, and the cardiovascular-risk patient population that ORAL Surveillance studied is prevalent in RA clinics.

TYK2 inhibitors offer a genuinely different approach. Deucravacitinib (Sotyktu, already FDA-approved October 2022 for plaque psoriasis) inhibits TYK2's regulatory pseudokinase domain rather than its active kinase domain — an allosteric mechanism that produces selectivity without affecting JAK1/2/3. In POETYK PSO-1 (NCT03881059, n=666), deucravacitinib achieved 58.4% PASI 75 at 16 weeks vs. 35.1% for apremilast (p<0.001) and 53.6% for placebo. The Phase 2/3 program for RA and SLE is now underway. The question isn't whether TYK2 inhibition works — psoriasis approval validates the mechanism — it's whether the efficacy in RA and SLE justifies the position relative to existing therapies.

Obexelimab (Zenas BioPharma) takes a different angle entirely. This bispecific antibody simultaneously targets CD19 (B cell marker) and FcγRIIb (inhibitory Fc receptor on B cells) — the combination activates the inhibitory receptor while engaging CD19, producing B cell suppression through a tolerogenic rather than depletive mechanism. Phase 3 trials in RA, IgA nephropathy, and pemphigus are enrolling. The Phase 2 RA data showed meaningful ACR response rates with a notably clean safety profile, which has attracted attention given the JAK inhibitor landscape.

Drug-free remission in RA deserves its own discussion. The AVERT trial (NCT01142726) tested abatacept in early RA and showed that a subset of patients maintained remission after biologic discontinuation; the RETRO study (NCT01438788) and the SPARE trial (NCT02614963) tested tapering and discontinuation strategies in sustained biologic-induced remission. Across these studies, roughly 25–35% of carefully selected patients maintain disease-free remission at 12 months after discontinuation. Predictors in development include anti-CCP negativity at baseline, power Doppler ultrasound remission confirmation, DAS28-CRP below a specific threshold, and emerging biomarkers including IL-6, CRP normalization, and specific regulatory T cell subset expansion. If these predictors hold up, we could meaningfully stratify who can safely stop biologics — a question that is deeply clinically relevant and almost never discussed with patients who are doing well on treatment.

Lupus Trials: Building on Anifrolumab's Foundation

Anifrolumab's approval in August 2021 for moderate-to-severe SLE was based primarily on TULIP-2 (NCT02547922, n=362). The BICLA response rate — defined as reduction in affected BILAG organ systems without worsening elsewhere — was 47.8% for anifrolumab vs. 31.5% for placebo (p=0.001). That's a meaningful but not overwhelming effect size. What's clinically notable is the oral corticosteroid-sparing effect: anifrolumab patients reduced prednisone to ≤7.5 mg/day at 40 weeks at significantly higher rates than placebo. TULIP-1 (NCT02446912) failed its primary SRI-4 endpoint (36.2% vs. 39.5%), which created confusion about interpretation — the difference in results between the two trials comes down to endpoint choice and measurement criteria, not to a different drug in a different disease.

The 2026 lupus pipeline extends well beyond interferon blockade. Telitacicept (RemeGen) is the most anticipated agent. This recombinant fusion protein blocks both BLyS (BAFF) and APRIL simultaneously by presenting the TACI receptor as a decoy — preventing both cytokines from engaging their native receptors on B cells and plasma cells. Belimumab (anti-BLyS) blocks only BLyS, allowing APRIL-dependent plasma cell survival to continue. Telitacicept's dual blockade is more complete. In a Chinese Phase 2 trial (NCT03910322, n=249), telitacicept 240mg weekly achieved 79% SRI-4 response vs. 32% for placebo at 52 weeks — a result that, if genuine, would be among the strongest efficacy signals in SLE trial history. The Phase 3 trials enrolling in the US and Europe are testing whether this effect holds in a Western population with different comorbidities, prior treatment history, and regulatory requirements. Results expected 2026.

Obinutuzumab (Gazyva, Roche) is a glycoengineered Type II anti-CD20 antibody with enhanced antibody-dependent cellular cytotoxicity compared to rituximab. In NOBILITY (NCT02550652, Phase 2, n=125) for lupus nephritis, obinutuzumab plus standard of care achieved renal complete response at 52 weeks in 35% of patients vs. 23% for placebo plus standard of care (p=0.115 — not significant, but the trend is consistent and the Phase 3 REGENCY trial is enrolling based on an agreed interim endpoint with FDA). Lupus nephritis affects up to 50% of SLE patients over the disease course and accounts for significant long-term morbidity; having an effective add-on to mycophenolate and corticosteroids matters clinically.

Frexalimab and tegoprubart target CD40L (CD154), a critical costimulatory molecule expressed on activated T cells that drives B cell activation through CD40 engagement. Earlier CD40L-targeting antibodies (like BI-655064) caused thrombotic events because platelets express CD40L and platelet-FcγRIIA engagement caused platelet aggregation. Both frexalimab and tegoprubart use engineered Fc regions that eliminate FcγRIIA binding while preserving CD40L blockade — an attempt to retain the therapeutic mechanism while eliminating the safety liability. Phase 2 data for both agents in SLE is expected in 2026.

IBD Trials: The VEGA Combination Surprise and What Follows

The VEGA Phase 2 trial results (published NEJM Evidence 2022) genuinely surprised gastroenterologists who had been skeptical that combining biologics would add meaningful benefit over monotherapy. In moderate-to-severe ulcerative colitis (n=214), the trial compared guselkumab (anti-IL-23p19) plus golimumab (anti-TNF), each monotherapy alone, and placebo. At week 12, clinical remission rates were: combination 83.1%, guselkumab alone 61.4%, golimumab alone 55.7%, placebo 24.8%. The combination-vs.-monotherapy difference was significant (p<0.001 for each comparison), with an effect size substantially larger than what sequential biologic failures achieve in clinical practice.

Why does the combination work? Guselkumab blocks IL-23-driven Th17 inflammation — a downstream pathway that produces IL-17, a potent epithelial and stromal activator. Golimumab blocks TNF, a proximal mediator of acute inflammation and tissue damage. These pathways are partially independent: blocking one doesn't automatically block the other, and patients with active disease often have both pathways engaged simultaneously. Whether the VEGA signal is reproduced in the Phase 3 EXPLORER trial (NCT05736536) will determine whether combination biologic therapy becomes standard of care for IBD — with substantial implications for cost, monitoring requirements, infection risk, and patient eligibility for future trials.

The JAK inhibitor story in IBD is more straightforward. Upadacitinib (SELECT-UC trials) and filgotinib (SELECTION trial) have completed Phase 3 in UC with strong efficacy data. Upadacitinib Phase 3 in Crohn's disease (U-ACHIEVE Maintenance, NCT03345836) showed 39.8% clinical remission at 52 weeks vs. 14.4% for placebo, completing the JAK inhibitor approval pathway for Crohn's. The same cardiovascular and malignancy safety considerations from ORAL Surveillance apply — UC and Crohn's patients tend to be younger on average than RA patients, which partially mitigates risk, but the boxed warning requirement shapes prescribing patterns in IBD just as in rheumatology.

S1P receptor modulators have established oral alternatives to biologic therapy for UC. Etrasimod (Velsipity, Pfizer, approved 2023) and ozanimod (Zeposia, approved 2021) retain lymphocytes in lymph nodes, reducing gut-homing lymphocyte trafficking. Neither achieves the remission rates of vedolizumab or upadacitinib in head-to-head comparisons, but patients who prefer or require a non-injectable regimen — a real and valid clinical preference — now have meaningful options. Dupilumab's approval in eosinophilic esophagitis (2022), COPD (2024), and its dominant position in atopic dermatitis and asthma continues to establish IL-4/IL-13 axis blockade as perhaps the most validated cytokine target across allergic and eosinophilic conditions.

Finding Autoimmune Disease Trials: A Practical Guide

Rheumatology, gastroenterology, dermatology, and neurology academic practices are the primary trial sites. The highest-volume autoimmune disease research centers include Johns Hopkins (rheumatology and lupus nephritis), Mayo Clinic (systemic autoimmune diseases), UCSF (SLE and myositis), Northwestern (RA and inflammatory arthritis), Columbia (lupus), Hospital for Special Surgery in New York (RA, myositis), and the Erlangen University Hospital group in Germany (CAR-T programs). Most have pre-screened patient waitlists for studies in development phase.

The most reliable search approach for ClinicalTrials.gov: filter by condition + "Recruiting" + your geographic region, and pay attention to the "Eligibility Criteria" tab before contacting a site. Most refractory disease trials have specific prior treatment requirements (e.g., "failed at least 2 biologics with different mechanisms of action") that eliminate a large proportion of interested patients before the first screening visit.

Condition-specific organizations with patient-facing trial navigation services: Lupus Research Alliance (lupusresearch.org) maintains a dedicated trial finder with study navigators; Myositis Association (myositis.org) tracks CAR-T studies specifically; Arthritis Foundation (arthritis.org) has an "arthritis by the numbers" trial finder. For CAR-T trials in SLE and myositis specifically, the most efficient approach is direct contact with the RESET-SLE team at Stanford or Penn, or the RESCUE team at Erlangen — they can assess eligibility remotely based on medical records before requiring an in-person visit.

Key Takeaways

• Anti-CD19 CAR-T therapy (Mackensen et al., Nature Medicine 2022/2024) achieved drug-free clinical remission in all 15 patients with severe refractory SLE, myositis, and systemic sclerosis in Phase 1/2 data, with 2+ year follow-up in the earliest patients. Phase 2 RESET-SLE (NCT05765072) and RESCUE-myositis are now enrolling at specialized centers.
• Anifrolumab TULIP-2 (NCT02547922) established 47.8% vs. 31.5% BICLA response (p=0.001) for SLE, and telitacicept showed 79% vs. 32% SRI-4 response in Phase 2 (n=249) — Phase 3 data from WESTERN populations is the key 2026 readout.
• TYK2 inhibitors (deucravacitinib) use allosteric pseudokinase domain binding to avoid JAK1/2 off-target effects. Phase 3 RA/SLE trials are enrolling as a safer alternative following ORAL Surveillance MACE and malignancy signals with tofacitinib.
• VEGA Phase 2 established guselkumab plus golimumab combination biologic therapy producing 83.1% UC clinical remission vs. 61.4% and 55.7% for monotherapies alone (p<0.001). Phase 3 EXPLORER (NCT05736536) will determine if this becomes standard of care.
• Drug-free RA remission trials AVERT, RETRO, and SPARE show 25–35% of patients in sustained biologic-induced remission maintain remission after discontinuation at 12 months — clinical and biomarker predictors (anti-CCP status, ultrasound remission, DAS28-CRP threshold) are actively being validated.
• Obinutuzumab (NOBILITY Phase 2, NCT02550652) showed 35% vs. 23% renal complete response in lupus nephritis; Phase 3 REGENCY is enrolling. Frexalimab and tegoprubart use engineered Fc regions to eliminate the thrombotic risk of earlier CD40L agents while preserving the B-T costimulatory blockade mechanism.